calcium formate

Phase 2Small molecule

PPei-Rong Ding

calcium formate is one of 6 small molecule programs targeting Organ Preservation. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Organ PreservationRecruiting

Organ PreservationPhase 2

Recruiting

Competition

Competitive Landscape

5 competitors in Organ Preservation

#DrugCompanyPhaseTrials

Eloxatin

Teva

Phase 2

2 2

Camptosar

Pfizer

Phase 2

1 3

Xeloda

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

4 4

Adrucil

EElorac, Inc.

Phase 2

1 5

FOLFOX

AstraZeneca

Phase 1

1 6

calcium formate

PPei-Rong Ding

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Female1 trial

Evaluation of the Ocular Safety of Calcium Formate in Normal, Healthy Female Subjects

Completed·UUniversity of Wisconsin, Madison·Phase 1·NCT00204893·12 enrolled

Organ Preservation1 trial

Short-course Radiotherapy or Long-course Chemoradiation Followed by MFOLFOXIRI Consolidation Chemotherapy for Organ Preservation in Low Rectal Cancer

Recruiting·PPei-Rong Ding·Phase 2·NCT06417476·66 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for calcium formate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — calcium formate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for calcium formate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pei-Rong Ding company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: PPei-Rong Ding

calcium formate

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Female1 trial

Organ Preservation1 trial

References

Drug Info

Quick Facts

Related News